Executive Medical Director, Clinical Sciences, Rare Diseases and HematologyTakeda Development Center Americas, Inc., Cambridge, MA, USACambridge, Massachusetts, United States
OC 14.1 - Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura
Sunday, June 25, 202310:45 – 11:00 ET
OC 14.2 - Pharmacokinetic characteristics of ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura: Interim results from a phase 3 randomized, controlled, open-label, crossover study
Sunday, June 25, 202311:00 – 11:15 ET
OC 14.4 - Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: interim analysis from phase 3b continuation study
Sunday, June 25, 202311:30 – 11:45 ET
